321 related articles for article (PubMed ID: 8849237)
1. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.
Zurenko GE; Yagi BH; Schaadt RD; Allison JW; Kilburn JO; Glickman SE; Hutchinson DK; Barbachyn MR; Brickner SJ
Antimicrob Agents Chemother; 1996 Apr; 40(4):839-45. PubMed ID: 8849237
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
Patel R; Rouse MS; Piper KE; Steckelberg JM
Diagn Microbiol Infect Dis; 1999 Jun; 34(2):119-22. PubMed ID: 10354862
[TBL] [Abstract][Full Text] [Related]
3. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.
Jones RN; Johnson DM; Erwin ME
Antimicrob Agents Chemother; 1996 Mar; 40(3):720-6. PubMed ID: 8851600
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.
Rybak MJ; Cappelletty DM; Moldovan T; Aeschlimann JR; Kaatz GW
Antimicrob Agents Chemother; 1998 Mar; 42(3):721-4. PubMed ID: 9517963
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci.
Noskin GA; Siddiqui F; Stosor V; Hacek D; Peterson LR
Antimicrob Agents Chemother; 1999 Aug; 43(8):2059-62. PubMed ID: 10428937
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.
Kaatz GW; Seo SM
Antimicrob Agents Chemother; 1996 Mar; 40(3):799-801. PubMed ID: 8851617
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1beta-methylcarbapenems with potent activities against multiresistant gram-positive bacteria.
Ueda Y; Sunagawa M
Antimicrob Agents Chemother; 2003 Aug; 47(8):2471-80. PubMed ID: 12878507
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities in new oxazolidinone antimicrobial agents against enterococci.
Eliopoulos GM; Wennersten CB; Gold HS; Moellering RC
Antimicrob Agents Chemother; 1996 Jul; 40(7):1745-7. PubMed ID: 8807077
[TBL] [Abstract][Full Text] [Related]
9. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections.
Ford CW; Hamel JC; Wilson DM; Moerman JK; Stapert D; Yancey RJ; Hutchinson DK; Barbachyn MR; Brickner SJ
Antimicrob Agents Chemother; 1996 Jun; 40(6):1508-13. PubMed ID: 8726028
[TBL] [Abstract][Full Text] [Related]
10. In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae.
Mason EO; Lamberth LB; Kaplan SL
Antimicrob Agents Chemother; 1996 Apr; 40(4):1039-40. PubMed ID: 8849225
[TBL] [Abstract][Full Text] [Related]
11. The in-vitro activity of linezolid (U-100766) and tentative breakpoints.
Wise R; Andrews JM; Boswell FJ; Ashby JP
J Antimicrob Chemother; 1998 Dec; 42(6):721-8. PubMed ID: 10052894
[TBL] [Abstract][Full Text] [Related]
12. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species.
Jorgensen JH; McElmeel ML; Trippy CW
Antimicrob Agents Chemother; 1997 Feb; 41(2):465-7. PubMed ID: 9021209
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.
Rybak MJ; Hershberger E; Moldovan T; Grucz RG
Antimicrob Agents Chemother; 2000 Apr; 44(4):1062-6. PubMed ID: 10722513
[TBL] [Abstract][Full Text] [Related]
14. Antibacterial oxazolidinones. In vitro activity of a new analogue, E3709.
Brumfitt W; Hamilton-Miller JM
Diagn Microbiol Infect Dis; 1992; 15(7):621-5. PubMed ID: 1424519
[TBL] [Abstract][Full Text] [Related]
15. Linezolid.
Clemett D; Markham A
Drugs; 2000 Apr; 59(4):815-27; discussion 828. PubMed ID: 10804037
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105.
Neu HC; Novelli A; Saha G; Chin NX
Antimicrob Agents Chemother; 1988 Apr; 32(4):580-3. PubMed ID: 3377467
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of two ketolides, HMR 3647 and HMR 3004, against gram-positive bacteria.
Malathum K; Coque TM; Singh KV; Murray BE
Antimicrob Agents Chemother; 1999 Apr; 43(4):930-6. PubMed ID: 10103202
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.
Sweeney MT; Zurenko GE
Antimicrob Agents Chemother; 2003 Jun; 47(6):1902-6. PubMed ID: 12760865
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis.
Mulazimoglu L; Drenning SD; Yu VL
Antimicrob Agents Chemother; 1996 Oct; 40(10):2428-30. PubMed ID: 8891159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
